Current Immunotherapeutic Strategies for Central Nervous System Tumors

Surgical Oncology Clinics of North America

Volumn 16, Issue 4, 2007, Pages 987-1004

  Kushen, Medina C ^a   Sonabend, Adam M ^a   Lesniak, Maciej S ^a  

^a Chicago Brain Tumor Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; INTERLEUKIN 13 PE38QQR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 (38 37) PE38KDEL; MAJOR HISTOCOMPATIBILITY ANTIGEN; NBI 3001; RECOMBINANT INTERLEUKIN 12; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DENDRITIC CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOMODULATION; NEUROTOXICITY; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION;

CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY;

EID: 36049009481     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.003     Document Type: Review

References (87)

1. Janeway C., Travers P., and Walport M. Immunobiology: the immune system in health and disease (1999), Current Biology Publications, New York
2. Holladay F.P., Heitz T., and Wood G.W. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77 5 (1992) 757-762
3. Prins R.M., and Liau L.M. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 53 1 (2003) 144-152 [discussion: 144-52]
4. Lampson B.C. Basic principles of CNS immunology (2002), WB Saunders, Philadelphia
5. Aloisi F., Ria F., Penna G., et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160 10 (1998) 4671-4680
6. Aloisi F. Immune function of microglia. Glia 36 2 (2001) 165-179
7. de Vos A.F., van Meurs M., Brok H.P., et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 169 10 (2002) 5415-5423
8. Sethna M.P., and Lampson L.A. Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma. J Neuroimmunol 34 2-3 (1991) 121-132
9. Parney I.F., Farr-Jones M.A., Chang L.J., et al. Human glioma immunobiology in vitro: implications for immunogene therapy. Neurosurgery 46 5 (2000) 1169-1177 [discussion: 1169-78]
10. Weller M., Frei K., Groscurth P., et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines. J Clin Invest 94 3 (1994) 954-964
11. Walker P.R., Calzascia T., Schnuriger V., et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 165 6 (2000) 3128-3135
12. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 28 2 (1991) 254-260
13. Perry V.H., Anthony D.C., Bolton S.J., et al. The blood-brain barrier and the inflammatory response. Mol Med Today 3 8 (1997) 335-341
14. Dix A.R., Brooks W.H., Roszman T.L., et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 1-2 (1999) 216-232
15. Gordon F.L., Nguyen K.B., White C.A., et al. Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol 112 1-2 (2001) 15-27
16. Matsumoto Y., Ohmori K., and Fujiwara M. Immune regulation by brain cells in the central nervous system: microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76 2 (1992) 209-216
17. Ito A., Shinkai M., Honda H., et al. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 50 10 (2001) 515-522
18. Prins R.M., and Liau L.M. Cellular immunity and immunotherapy of brain tumors. Front Biosci 9 (2004) 3124-3136
19. Wiendl H., Mitsdoerffer M., Hofmeister V., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168 9 (2002) 4772-4780
20. Wiendl H., Mitsdoerffer M., and Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 13 5 (2003) 343-351
21. Morford L.A., Elliott L.H., Carlson S.L., et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159 9 (1997) 4415-4425
22. Prins R.M., Graf M.R., and Merchant R.E. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 50 6 (2001) 285-292
23. Olofsson A., Miyazono K., Kanzaki T., et al. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line: identification of small and different forms of large latent complexes. J Biol Chem 267 27 (1992) 19482-19488
24. Kuppner M.C., Hamou M.F., Sawamura Y., et al. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71 2 (1989) 211-217
25. Kehrl J.H., Roberts A.B., Wakefield L.M., et al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 137 12 (1986) 3855-3860
26. Rook A.H., Kehrl J.H., Wakefield L.M., et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136 10 (1986) 3916-3920
27. Kehrl J.H., Wakefield L.M., Roberts A.B., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163 5 (1986) 1037-1050
28. Zuber P., Kuppner M.C., and De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18 10 (1988) 1623-1626
29. Jensen R.L. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49 2 (1998) 189-195 [discussion: 196]
30. Kuppner M.C., Sawamura Y., Hamou M.F., et al. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J Neurosurg 72 4 (1990) 619-625
31. Yamanaka R., Tanaka R., Yoshida S., et al. Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. J Neurooncol 43 1 (1999) 27-34
32. Krakowski M.L., and Owens T. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis. Eur J Immunol 27 11 (1997) 2840-2847
33. Glick R.P., Lichtor T., de Zoeten E., et al. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45 4 (1999) 867-874
34. Okada H., Giezeman-Smits K.M., Tahara H., et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 6 2 (1999) 219-226
35. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 22 20 (2003) 3188-3192
36. Sampath P., Hanes J., DiMeco F., et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59 9 (1999) 2107-2114
37. Ferrantini M., Giovarelli M., Modesti A., et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity: comparative studies with IFN-gamma-producing TS/A cells. J Immunol 153 10 (1994) 4604-4615
38. Hiroishi K., Tuting T., Tahara H., et al. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther 6 12 (1999) 1988-1994
39. Lo C.H., Lee S.C., Wu P.Y., et al. Antitumor and antimetastatic activity of IL-23. J Immunol 171 2 (2003) 600-607
40. Tahara H., Zitvogel L., Storkus W.J., et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154 12 (1995) 6466-6474
41. Okada H., and Pollack I.F. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4 10 (2004) 1609-1620
42. Dillman R.O., Duma C.M., Schiltz P.M., et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 5 (2004) 398-404
43. Kruse C.A., Cepeda L., Owens B., et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45 2 (1997) 77-87
44. Colombo F., Barzon L., Franchin E., et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12 10 (2005) 835-848
45. Okada H., Lieberman F.S., Edington H.D., et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64 1-2 (2003) 13-20
46. Kikuchi T., Akasaki Y., Abe T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 6 (2004) 452-459
47. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92 2 (2001) 420-433
48. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
49. Steinman R.M., Pack M., and Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 156 (1997) 25-37
50. Gourmala N.G., Buttini M., Limonta S., et al. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 74 1-2 (1997) 35-44
51. Grabbe S., Kampgen E., and Schuler G. Dendritic cells: multi-lineal and multi-functional. Immunol Today 21 9 (2000) 431-433
52. Kikuchi T., Akasaki Y., Irie M., et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 7 (2001) 337-344
53. Jonuleit H., Giesecke A., Kandemir A., et al. Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Arch Dermatol Res 292 7 (2000) 325-332
54. Ashley D.M., Faiola B., Nair S., et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186 7 (1997) 1177-1182
55. Boczkowski D., Nair S.K., Snyder D., et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184 2 (1996) 465-472
56. Aoki H., Mizuno M., Natsume A., et al. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50 9 (2001) 463-468
57. Heimberger A.B., Crotty L.E., Archer G.E., et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103 1 (2000) 16-25
58. Ni H.T., Spellman S.R., Jean W.C., et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51 1 (2001) 1-9
59. Lassmann H., Schmied M., Vass K., et al. Bone marrow derived elements and resident microglia in brain inflammation. Glia 7 1 (1993) 19-24
60. Fossum S. Lymph-borne dendritic leucocytes do not recirculate, but enter the lymph node paracortex to become interdigitating cells. Scand J Immunol 27 1 (1988) 97-105
61. Everson M.P., McDuffie D.S., Lemak D.G., et al. Dendritic cells from different tissues induce production of different T cell cytokine profiles. J Leukoc Biol 59 4 (1996) 494-498
62. Morikawa Y., Tohya K., Ishida H., et al. Different migration patterns of antigen-presenting cells correlate with Th1/Th2-type responses in mice. Immunology 85 4 (1995) 575-581
63. Yamanaka R., Yajima N., Tsuchiya N., et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with semliki forest virus-mediated tumor complementary DNA. J Neurosurg 97 5 (2002) 1184-1190
64. Insug O., Ku G., Ertl H.C., et al. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22 2A (2002) 613-621
65. Nishioka Y., Hirao M., Robbins P.D., et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res 59 16 (1999) 4035-4041
66. Yamanaka R., Zullo S.A., Ramsey J., et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing semliki forest virus-mediated interleukin-12. J Neurosurg 97 3 (2002) 611-618
67. Yamanaka R., Abe T., Yajima N., et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 7 (2003) 1172-1179
68. Yu J.S., Wheeler C.J., Zeltzer P.M., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 3 (2001) 842-847
69. Miyatake S., Martuza R.L., and Rabkin S.D. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 4 4 (1997) 222-228
70. Parker J.N., Gillespie G.Y., Love C.E., et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 97 5 (2000) 2208-2213
71. Andreansky S., He B., van Cott J., et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5 1 (1998) 121-130
72. Yoshikawa K., Kajiwara K., Ideguchi M., et al. Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4. Cancer Immunol Immunother 49 1 (2000) 23-33
73. Liu Y., Ehtesham M., Samoto K., et al. In situ adenoviral interleukin-12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9 1 (2002) 9-15
74. Yamini B., Yu X., Gillespie G.Y., et al. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res 64 18 (2004) 6381-6384
75. Allen C., Vongpunsawad S., Nakamura T., et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 66 24 (2006) 11840-11850
76. Eguchi J., Hatano M., Nishimura F., et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66 11 (2006) 5883-5891
77. *0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8 9 (2002) 2851-2855
78. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91 6 (1994) 2076-2080
79. Chiocca E.A., Broaddus W.C., Gillies G.T., et al. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 69 1-3 (2004) 101-117
80. Hall W.A., Rustamzadeh E., and Asher A.L. Convection-enhanced delivery in clinical trials. Neurosurg Focus 14 2 (2003) 1-4
81. Rainov N.G., and Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol 66 1-2 (2004) 197-201
82. Weber F., Asher A., Bucholz R., et al. Safety, tolerability, and tumor response of IL4-pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64 1-2 (2003) 125-137
83. Rand R.W., Kreitman R.J., Patronas N., et al. Intratumoral administration of recombinant circularly permuted interleukin-4-pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6 6 (2000) 2157-2165
84. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88 (2003) 105-111
85. Joshi B.H., Plautz G.E., and Puri R.K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60 5 (2000) 1168-1172
86. Sampson J.H., Reardon D.A., Friedman A.H., et al. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol 7 1 (2005) 90-96
87. Weber F.W., Floeth F., Asher A., et al. Local convection enhanced delivery of IL4-pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88 (2003) 93-103